Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
INmune Bio Inc. - Common stock
(NQ:
INMB
)
2.105
+0.015 (+0.72%)
Streaming Delayed Price
Updated: 3:25 PM EDT, Aug 10, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about INmune Bio Inc. - Common stock
< Previous
1
2
3
4
5
6
7
8
9
Next >
INmune Bio (INMB) Q2 2026 Earnings Call Transcript
↗
August 07, 2026
Ebstracel nears UK filing as XPro shows Alzheimer's biomarker progress.
Via
The Motley Fool
Topics
Earnings
INmune Bio Q2 Earnings Call Highlights
↗
August 06, 2026
INmune Bio (NASDAQ:INMB) outlined plans to file for conditional approval of its Ebstrocel cell therapy in the United Kingdom by the end of the third quarter or early in the fourth quarter of 2026,...
Via
MarketBeat
Topics
Earnings
INmune Bio (NASDAQ:INMB) Beats Q2 Loss Estimates but Shares Tumble on Business Update
↗
August 06, 2026
Via
Chartmill
INmune Bio Receives R&D Rebates of Approximately $4.6 Million
July 31, 2026
From
INmune Bio, Inc.
Via
GlobeNewswire
INMUNE BIO INC (NASDAQ:INMB) Beats Q1 2026 EPS Estimates as Stock Shows Recent Momentum
↗
May 07, 2026
Via
Chartmill
INMB Stock Rises Pre-Market – What Did The FDA Say About Its Alzheimer’s Trial?
↗
February 12, 2026
Via
Stocktwits
INmune Bio Inc. to Report Second Quarter 2026 Financial Results and Provide Corporate Update on Thursday, August 6th
July 31, 2026
From
INmune Bio, Inc.
Via
GlobeNewswire
INmune Bio Establishes Scientific Advisory Board to Support Late-Stage Development and Expansion of CORDStrom™ Platform
July 30, 2026
From
INmune Bio, Inc.
Via
GlobeNewswire
INmune Bio Completes Commercial Manufacturing Milestone Supporting Planned Global Registration Filings for CORDStrom™ Platform
July 20, 2026
From
INmune Bio, Inc.
Via
GlobeNewswire
INmune Bio’s XPro1595 Prevents Brain-Injury-Induced Alzheimer's Pathology, Memory Loss, and Pain in New Peer-Reviewed Preclinical Study
July 15, 2026
From
INmune Bio, Inc.
Via
GlobeNewswire
INmune Bio to Present Positive Phase 2 Imaging Data for XPro in Early Alzheimer’s Disease at AAIC
July 09, 2026
From
INmune Bio, Inc.
Via
GlobeNewswire
INmune Bio Advances CORDStrom™ Platform Patent Application in the U.S. Following Favorable International Written Opinion
July 01, 2026
From
INmune Bio, Inc.
Via
GlobeNewswire
INmune Bio Inc. Achieves MHRA Approval of PIP for CORDStrom™
June 25, 2026
From
INmune Bio, Inc.
Via
GlobeNewswire
INmune Bio Receives MHRA Written Alignment Supporting Planned 2026 UK Conditional Marketing Authorization Application for CORDStrom™ in RDEB
June 23, 2026
From
INmune Bio, Inc.
Via
GlobeNewswire
INmune Bio Reports Statistically Significant Treatment Effect on Advanced White Matter MRI Biomarker in Phase 2 MINDFuL Alzheimer's Trial
June 02, 2026
From
INmune Bio, Inc.
Via
GlobeNewswire
INmune Bio (INMB) Q4 2025 Earnings Transcript
↗
June 01, 2026
INmune Bio (INMB) Q4 2025 Earnings Transcript
Via
The Motley Fool
INmune Bio Publishes Phase 2 MINDFuL Trial Results in NPJ Dementia, Advancing the XPro™ Platform
May 15, 2026
From
INmune Bio, Inc.
Via
GlobeNewswire
INmune Bio Receives FDA Fast Track Designation for XPro1595 in Early Alzheimer's Disease
May 14, 2026
From
INmune Bio, Inc.
Via
GlobeNewswire
INmune Bio Named Founding Member of the American Biotech Innovation Alliance (ABIA) as U.S. Biotech Sector Navigates Strategic Inflection Point
May 13, 2026
From
INmune Bio, Inc.
Via
GlobeNewswire
INmune Bio (INMB) Q1 2026 Earnings Transcript
↗
May 08, 2026
INmune Bio (INMB) Q1 2026 Earnings Transcript
Via
The Motley Fool
Topics
Economy
INmune Bio and Anthony Nolan Announce Strategic Expansion of CORDStrom™ MSC Platform Collaboration to Target RDEB, Oncology, and Inflammatory Diseases
May 05, 2026
From
INmune Bio, Inc.
Via
GlobeNewswire
INmune Bio Inc. to Report First Quarter 2026 Financial Results and Provide Corporate Update on Thursday, May 7th
April 30, 2026
From
INmune Bio, Inc.
Via
GlobeNewswire
INmune Bio Inc. Announces New Preclinical Data at AACR 2026 Demonstrating INB03 (XPro1595) Overcomes Resistance and Reduces Metastases in HER2-Positive Breast Cancer Models
April 16, 2026
From
INmune Bio, Inc.
Via
GlobeNewswire
INmune Bio Inc. to Report Year End 2025 Financial Results and Provide Corporate Update on Monday, March 30th.
March 24, 2026
From
INmune Bio, Inc.
Via
GlobeNewswire
INmune Bio’s MINDFuL Trial Featured at AD/PD 2026 Plenary as Successful Example of How to Approach Clinical Trials Targeting Inflammation in Early Alzheimer’s Disease
March 19, 2026
From
INmune Bio, Inc.
Via
GlobeNewswire
INmune Bio to Detail XPro1595 Registrational Strategy in Upcoming Alzheimer’s Webinar
February 23, 2026
Webinar on February 27 at 9:30 AM ET will have key opinion leaders discuss recent and upcoming clinical development of XPro1595
From
INmune Bio, Inc.
Via
GlobeNewswire
INmune Bio Announces Upcoming Webinar to Present New Clinical Data on CORDStrom™ for RDEB
February 19, 2026
From
INmune Bio, Inc.
Via
GlobeNewswire
INmune Bio Announces FDA Alignment on Integrated Phase 2b/3 Registration Pathway for XPro1595 in Early Alzheimer’s Disease
February 12, 2026
From
INmune Bio, Inc.
Via
GlobeNewswire
INmune Bio Advances CORDStrom™ Towards UK Marketing Authorization in RDEB
February 10, 2026
From
INmune Bio, Inc.
Via
GlobeNewswire
INmune Bio Inc Issues Shareholder Letter Reviewing 2025 Milestones and Outlining 2026 Strategic Initiatives
January 27, 2026
From
INmune Bio, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
